Global BulletinAll NewsFDA Approval AlertWomen in Oncology
Around the PracticeBetween the LinesFace OffFrom All AnglesMeeting of the MindsOncViewPodcastsTraining AcademyTreatment Algorithms with the Oncology BrothersVideos
Conferences
All JournalsEditorial BoardFor AuthorsYear in Review
Frontline ForumSatellite Sessions
CME/CE
Awareness MonthNurse Practitioners/Physician's AssistantsPartnersSponsoredSponsored Media
Career CenterSubscribe
Adverse Effects
Brain Cancer
Breast CancerBreast CancerBreast Cancer
Gastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal Cancer
Genitourinary CancersGenitourinary CancersGenitourinary CancersGenitourinary Cancers
Gynecologic CancersGynecologic CancersGynecologic CancersGynecologic Cancers
Head & Neck Cancer
Hematologic OncologyHematologic OncologyHematologic OncologyHematologic Oncology
InfectionInfection
Leukemia
Lung CancerLung CancerLung Cancer
Lymphoma
Neuroendocrine Tumors
Oncology
Pediatric Cancers
Radiation Oncology
Sarcoma
Screening
Skin Cancer & Melanoma
Surgery
Thyroid Cancer
Spotlight -
  • Radiation Oncology
  • Surgery
Adverse Effects
Brain Cancer
Breast CancerBreast CancerBreast Cancer
Gastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal Cancer
Genitourinary CancersGenitourinary CancersGenitourinary CancersGenitourinary Cancers
Gynecologic CancersGynecologic CancersGynecologic CancersGynecologic Cancers
Head & Neck Cancer
Hematologic OncologyHematologic OncologyHematologic OncologyHematologic Oncology
InfectionInfection
Leukemia
Lung CancerLung CancerLung Cancer
Lymphoma
Neuroendocrine Tumors
Oncology
Pediatric Cancers
Radiation Oncology
Sarcoma
Screening
Skin Cancer & Melanoma
Surgery
Thyroid Cancer
    • Conferences
    • CME/CE
    • Career Center
    • Subscribe
Advertisement

University of Minnesota Researchers Find Evidence of Genetic Link to Breast Density

June 1, 1997
Publication
Article
OncologyONCOLOGY Vol 11 No 6
Volume 11
Issue 6

Researchers at the University of Minnesota Cancer Center have found evidence that mamographic breast density, a measure of the relative proportions of fat, connective tissue, and glandular epithelial tissue in the breast that is a strong, independent

Researchers at the University of Minnesota Cancer Center have foundevidence that mamographic breast density, a measure of the relative proportionsof fat, connective tissue, and glandular epithelial tissue in the breastthat is a strong, independent predictor of breast cancer risk, is geneticallyinfluenced. The study, published in the April 16th Journal of the NationalCancer Institute, also suggests that 12% of the population has a geneticmutation that results in a breast density twice that of women without themutation.

"It isn't known how high breast density increases the risk of breastcancer," said lead investigator Thomas Sellers, associate professorof epidemiology and associate director of the Cancer Center. "Butthe risk is considered second only to the risk incurred by mutations inthe BRCA1 and BRCA2 genes."

The researchers obtained routine mammograms and a variety of health-relateddata from 1,370 women from 258 different Minnesota families. The studypopulation included 65 mother-daughter pairs and 275 sister-sister pairs.All of the women were related, either genetically or by marriage, to anoriginal group of 544 breast cancer patients seen at the University ofMinnesota between 1944 and 1952. Sellers and colleagues are studying thesefamilies as part of the Breast Cancer Family Cohort study.

Breast Density Partly Modifiable

Sellers says that the study is significant because the researchers wereable to separate out other risk factors, such as waist-to-hip ratio, physicalactivity, hormone replacement therapy, and number of live births, to detecta Mendelian dominant inheritance pattern (a pattern where only one copyof the mutated gene is necessary to transfer the trait to offspring). Theywere unable, however, to completely eliminate the possibility of a recessivepattern, which would require more than one copy of a gene to produce atrait. However, if breast density is, indeed, controlled by a dominantgene, about 12% of the population would be expected to carry a form ofthe gene that results in a breast density about twice that of the restof the population. "The good news is that while breast density riskfactor is partly genetic, it's also shaped by the environment, and so canbe modified," Sellers said.

In previous studies, Sellers and colleagues have reported on potentialrisk factors for breast cancer, including waist-to-hip ratio, fat in thediet, and the connection between breast cancer in women and prostate cancerin men. These finding stem from the Iowa Women's Study, an ongoing healthstudy of more than 40,000 women in Iowa.

Articles in this issue

Use of Adjuvent Analgesics Profiled at Pain Conference
Chromosomal Changes Linked to Family History of Lung Cancer
Bacterial Infection in Patients With Cancer: Focus on Prevention
Docetaxel in Combined Modality Therapy for Breast Cancer
Role of Diet in Cancer Hard to Study, Expert Says
Anti-HIV Effects of Viracept Persist During Long Periods of Combination Therapy
University of Minnesota Researchers Find Evidence of Genetic Link to Breast Density
Guidelines for the Early Referral of Patients to Cancer Specialists
New Drugs May Brighten Ovarian Cancer Picture
Researchers Hope Function of BRCA1 Gene Holds Key to New Treatments
Research Points to Effectiveness of Brachytherapy in Early Prostate
Lung Cancer Surgical Practice Guidelines
Pituitary Adenomas: Current Methods of Diagnosis and Treatment
Management of Carcinoma of the Superior Pulmonary Sulcus
SSO Practice Guidelines: Introductory Remarks
Recent Videos
The mechanism of CTO1681 may allow it to reduce the production of a broad range of proinflammatory cytokines in DLBCL.
Younger and fitter patients with relapsed/refractory multiple myeloma were more likely to receive bispecific antibodies in community oncology settings.
Mechanistic treatment benefits were observed in the phase 2 STEM trial for patients with multiple myeloma.
Data from a retrospective cohort study showed that one-fifth of patients with multiple myeloma received bispecific antibodies in rural community settings.
Being able to treat patients with cevostamab who have multiple myeloma after 1 to 3 prior lines of therapy vs 4 lines may allow for better outcomes.
Using the monitoring of symptoms and quality of life platform may provide a quick and efficient system for patients to submit outcome data.
2 experts are featured in this series.
With many treatments emerging in the EGFR-mutated lung cancer landscape, sequencing therapy has emerged as a key consideration for these patients.
Related Content
Advertisement

Among the 12 patients with suspected brain metastases treated with RAD 101, the images showed metabolic activity in brain metastases compared with MRI findings.

RAD 101 Imaging Agent Achieves Concordance with MRI in Suspected Brain Mets

Tim Cortese
December 16th 2025
Article

Among the 12 patients with suspected brain metastases treated with RAD 101, the images showed metabolic activity in brain metastases compared with MRI findings.


Experts share updated results on investigational hematologic oncology regimens that they presented at the 2025 ASH Meeting.

ASH 2025: Key Discussions in Multiple Myeloma, Lymphoma, and Leukemia

Krina K. Patel, MD, MSc;Manali Kamdar, MD;Wei Ying Jen, MA, BM BCh, M Med, MRCP, FRCPath
December 15th 2025
Podcast

Experts share updated results on investigational hematologic oncology regimens that they presented at the 2025 ASH Meeting.


Atezolizumab/NAT May Impact Fertility in TNBC

Atezolizumab/NAT May Impact Fertility in TNBC

Silas Inman
December 16th 2025
Article

Atezolizumab plus neoadjuvant therapy was found to increase chemotherapy-induced ovarian failure among patients with TNBC.


Why Sexual and Gender Minority Care is an Oncologic Imperative

Why Sexual and Gender Minority Care is an Oncologic Imperative

Daniel C. McFarland, DO;Charles S. Kamen, PhD, MPH
December 8th 2025
Podcast

Daniel C. McFarland, DO, and Charles S. Kamen, PhD, MPH, focused on cultural humility, nonverbal data collection, and tailored resources to improve care.


The decision is based on results from the phase 3 MajesTEC-3 trial, which showed a PFS benefit with the teclistamab combination in patients with pretreated multiple myeloma.

FDA Grants National Priority Voucher to Teclistamab/Daratumumab in RRMM

Tim Cortese
December 15th 2025
Article

The decision is based on results from the phase 3 MajesTEC-3 trial, which showed a PFS benefit with the teclistamab combination in patients with pretreated multiple myeloma.


Results from the phase 3 DESTINY-Breast09 trial led to the approval of T-DXd plus pertuzumab in unresectable/metastatic HER2+ breast cancer.

FDA Approves T-DXd Plus Pertuzumab in Metastatic HER2+ Breast Cancer

Tim Cortese
December 15th 2025
Article

Results from the phase 3 DESTINY-Breast09 trial led to the approval of T-DXd plus pertuzumab in unresectable/metastatic HER2+ breast cancer.

Related Content
Advertisement

Among the 12 patients with suspected brain metastases treated with RAD 101, the images showed metabolic activity in brain metastases compared with MRI findings.

RAD 101 Imaging Agent Achieves Concordance with MRI in Suspected Brain Mets

Tim Cortese
December 16th 2025
Article

Among the 12 patients with suspected brain metastases treated with RAD 101, the images showed metabolic activity in brain metastases compared with MRI findings.


Experts share updated results on investigational hematologic oncology regimens that they presented at the 2025 ASH Meeting.

ASH 2025: Key Discussions in Multiple Myeloma, Lymphoma, and Leukemia

Krina K. Patel, MD, MSc;Manali Kamdar, MD;Wei Ying Jen, MA, BM BCh, M Med, MRCP, FRCPath
December 15th 2025
Podcast

Experts share updated results on investigational hematologic oncology regimens that they presented at the 2025 ASH Meeting.


Atezolizumab/NAT May Impact Fertility in TNBC

Atezolizumab/NAT May Impact Fertility in TNBC

Silas Inman
December 16th 2025
Article

Atezolizumab plus neoadjuvant therapy was found to increase chemotherapy-induced ovarian failure among patients with TNBC.


Why Sexual and Gender Minority Care is an Oncologic Imperative

Why Sexual and Gender Minority Care is an Oncologic Imperative

Daniel C. McFarland, DO;Charles S. Kamen, PhD, MPH
December 8th 2025
Podcast

Daniel C. McFarland, DO, and Charles S. Kamen, PhD, MPH, focused on cultural humility, nonverbal data collection, and tailored resources to improve care.


The decision is based on results from the phase 3 MajesTEC-3 trial, which showed a PFS benefit with the teclistamab combination in patients with pretreated multiple myeloma.

FDA Grants National Priority Voucher to Teclistamab/Daratumumab in RRMM

Tim Cortese
December 15th 2025
Article

The decision is based on results from the phase 3 MajesTEC-3 trial, which showed a PFS benefit with the teclistamab combination in patients with pretreated multiple myeloma.


Results from the phase 3 DESTINY-Breast09 trial led to the approval of T-DXd plus pertuzumab in unresectable/metastatic HER2+ breast cancer.

FDA Approves T-DXd Plus Pertuzumab in Metastatic HER2+ Breast Cancer

Tim Cortese
December 15th 2025
Article

Results from the phase 3 DESTINY-Breast09 trial led to the approval of T-DXd plus pertuzumab in unresectable/metastatic HER2+ breast cancer.

Advertisement
About
Advertise
CureToday.com
OncLive.com
OncNursingNews.com
TargetedOnc.com
Editorial
Contact
Terms and Conditions
Privacy
Do Not Sell My Personal Information
Contact Info

2 Commerce Drive
Cranbury, NJ 08512

609-716-7777

© 2025 MJH Life Sciences

All rights reserved.